These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 11824696)

  • 21. Employing the Risk-Need-Responsivity (RNR) model and predicting successful completion in an alternative drug court program: Preliminary findings from the Orleans Parish Drug Court.
    Mikolajewski AJ; Allan NP; Merrill L; Carter MC; Manguno-Mire G
    J Subst Abuse Treat; 2021 Dec; 131():108453. PubMed ID: 34098284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rearrest and linkage to mental health services among clients of the Clark County mental health court program.
    Herinckx HA; Swart SC; Ama SM; Dolezal CD; King S
    Psychiatr Serv; 2005 Jul; 56(7):853-7. PubMed ID: 16020819
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluating corrections-based treatment for the drug-abusing criminal offender.
    Knight K; Hiller ML; Simpson DD
    J Psychoactive Drugs; 1999; 31(3):299-304. PubMed ID: 10533977
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Juvenile drug court: enhancing outcomes by integrating evidence-based treatments.
    Henggeler SW; Halliday-Boykins CA; Cunningham PB; Randall J; Shapiro SB; Chapman JE
    J Consult Clin Psychol; 2006 Feb; 74(1):42-54. PubMed ID: 16551142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Examining Individual Characteristics and Program Performance to Understand Two-Year Recidivism Rates Among Drug Court Participants: Comparing Graduates and Terminators.
    Shannon LM; Jones AJ; Newell J; Payne C
    Int J Offender Ther Comp Criminol; 2018 Oct; 62(13):4196-4220. PubMed ID: 29706118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Using latent class analysis to identify participant typologies in a drug treatment court.
    Larsen JL; Nylund-Gibson K; Cosden M
    Drug Alcohol Depend; 2014 May; 138():75-82. PubMed ID: 24598121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes among drug court participants: does drug of choice matter?
    Shaffer DK; Hartman JL; Listwan SJ; Howell T; Latessa EJ
    Int J Offender Ther Comp Criminol; 2011 Feb; 55(1):155-74. PubMed ID: 20110426
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic jurisprudence: judicial and corrections panel.
    Jessup M
    J Psychoactive Drugs; 2001; 33(4):355-67. PubMed ID: 11824695
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treating high-risk offenders in the community: the potential of drug courts.
    Koetzle D; Listwan SJ; Guastaferro WP; Kobus K
    Int J Offender Ther Comp Criminol; 2015 May; 59(5):449-65. PubMed ID: 24363291
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug treatment courts are popular but do they work and are they ethical and appropriate for Canada?
    Christie T; Anderson JF
    Health Law Can; 2003 May; 23(4):70-9. PubMed ID: 12845932
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Integrating the criminal justice system into mental health service delivery: the worcester diversion experience.
    Grudzinskas AJ; Clayfield JC; Roy-Bujnowski K; Fisher WH; Richardson MH
    Behav Sci Law; 2005; 23(2):277-93. PubMed ID: 15818600
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is the drug court model exportable? The cost-effectiveness of a driving-under-the-influence court.
    Eibner C; Morral AR; Pacula RL; MacDonald J
    J Subst Abuse Treat; 2006 Jul; 31(1):75-85. PubMed ID: 16814013
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug treatment courts--a viable option for Canada? Sentencing issues and preliminary findings from the Toronto court.
    La Prairie C; Gliksman L; Erickson PG; Wall R; Newton-Taylor B
    Subst Use Misuse; 2002; 37(12-13):1529-66. PubMed ID: 12487233
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early implementation of Proposition 36: criminal justice and treatment system issues in eight counties.
    Speiglman R; Klein D; Miller R; Noble A
    J Psychoactive Drugs; 2003 May; 35 Suppl 1():133-41. PubMed ID: 12825756
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proposition 36: issues and challenges.
    Jett KP
    J Psychoactive Drugs; 2001; 33(4):321-8. PubMed ID: 11824690
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exploring the opportunities of Proposition 36.
    Banys P
    J Psychoactive Drugs; 2001; 33(4):329-37. PubMed ID: 11824691
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nga Whenu Raranga/Weaving Strands in the Alcohol and Other Drug Treatment Court of Aotearoa/New Zealand.
    Thom K; Black S
    J Law Med; 2018 Apr; 25(3):727-740. PubMed ID: 29978664
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Are judicial status hearings a "key component" of drug court? Six and twelve months outcomes.
    Marlowe DB; Festinger DS; Dugosh KL; Lee PA
    Drug Alcohol Depend; 2005 Aug; 79(2):145-55. PubMed ID: 16002024
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reporting of substance use treatment quality in United States adult drug courts.
    Joudrey PJ; Howell BA; Nyhan K; Moravej A; Doernberg M; Ross JS; Wang EA
    Int J Drug Policy; 2021 Apr; 90():103050. PubMed ID: 33310636
    [TBL] [Abstract][Full Text] [Related]  

  • 40. What Matters More in Explaining Drug Court Graduation and Rearrest: Program Features, Individual Characteristics, or Some Combination.
    Breno A; Ramezani N; Guastaferro W; Cummings A; Murphy A; Taxman FS
    Int J Offender Ther Comp Criminol; 2023 Sep; 67(12):1211-1229. PubMed ID: 35450474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.